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Encephalitozoonosis is an opportunistic infection in animals and humans. Its
clinical form is observed in immunosuppressed hosts. We studied the occurrence of
the manifest form of rabbit microsporidiosis under cyclophosphamide immuno-
modulation in 40 New Zealand rabbits. The experimental animals were intraperito-
neally infected with 5 × 107 Encephalitozoon cuniculi spores. Two weeks after in-
fection the animals were treated intraperitoneally with cyclophosphamide, first with
50 mg/kg and then with 15 mg/kg weekly during the 12-week experimental period.
Positive controls were either E. cuniculi-infected or cyclophosphamide-immuno-
suppressed animals. The negative control rabbits remained untreated. Both clinical
signs of encephalitozoonosis and depression of peripheral blood cell count devel-
oped between weeks 4 and 6 in the experimental animals which died during week 6
of the experiment. No clinical signs compatible with encephalitozoonosis were ob-
served in any of the controls. The results suggest that immunosuppression induced
by cyclophosphamide can give rise to a lethal form of encephalitozoonosis.
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Encephalitozoonosis caused by Encephalitozoon cuniculi is a chronic,
usually latent protozoonosis of rodents, carnivores, birds and primates. E. cu-
niculi is an obligate intracellular parasite of the phylum Microspora (Pakes and
Gerrity, 1994). Clinical encephalitozoonosis is accompanied by neurological
signs, e.g. paralysis and convulsion (Bálent et al., 1995). In rabbits, Levkut et al.
(1997) have assumed that bovine leukaemia virus acts as a factor predisposing
rabbits to clinically apparent encephalitozoonosis. Lethal disease is typical of T-
and B-lymphocyte immunodeficient (SCID) mice (Koudela et al., 1993). Mi-
crosporidia have been referred to as opportunistic pathogens in humans with
AIDS (Weber et al., 1994). Recently, Mathis et al. (1997) has found a rabbit
E. cuniculi isolate, classified by Didier et al. (1995) as strain I, in the urine of
people, confirming the zoonotic character of the disease.
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Cyclophosphamide (CY) is an immunosuppressive, cytotoxic drug, a
chemical derivative of mechloretamine (Boumpas et al., 1993). CY has been
used in the therapy of neoplastic (De Forni and Armand, 1994) and autoimmune
diseases (Bradley et al., 1989). The immunosuppressive and cytotoxic effects of
CY are based upon an alkylating reaction with cell DNA (Steinberg, 1993).
Haematological toxicity is its best-known action. CY suppresses all cell lines
within the bone marrow. Maximal depression of circulating granulocytes and
lymphocytes occurs at 714 days after treatment with a single dose of CY
(McCune et al., 1988). Similarly, a single dose of CY led to a 60% decrease of
both T and B lymphocyte numbers in the spleen (Austin et al., 1997).
The aim of this work was to study the relationship between the quantita-
tive changes of peripheral leukocyte count and the occurrence of clinically mani-
fest encephalitozoonosis in rabbits immunosuppressed with cyclophosphamide.
Materials and methods
Parasite
A rabbit isolate of E. cuniculi (provided by a laboratory of O. Ditrich, Para-
sitology Institute, Czech Republic) was grown in E-6 cell (Vero green monkey
kidney cell) for provision of spores. The cells were cultivated in modified RPMI
1640 medium supplemented with 5% fetal calf serum. The parasites used for in-
oculation were freshly collected from the culture supernatant after centrifugation at
400 g for 30 min, washed by centrifugation in phosphate-buffered saline (PBS),
counted on haemocytometer, and adjusted to the desired concentration.
Animals and experimental procedure
Forty New Zealand White rabbits of both sexes (4 months old; 2.5 ±
0.5 kg in weight), free of E. cuniculi, coccidial and Pasteurella infection, were
used in the experiment. Four groups of ten rabbits each were housed under con-
ventional conditions with free access to water and feed. Animals of the first
group, designated as Ec+Cy+, were infected by intraperitoneal (i.p.) injection of
5 × 107 E. cuniculi spores in 1 ml PBS. In order to induce immunosuppression,
this group was treated intraperitoneally with two dosages of CY once weekly
during a period of 12 weeks. The first CY dosage of 50 mg/kg was applied on
day 14 after E. cuniculi administration, and then 15 mg/kg CY was given once a
week for period of 12 weeks.
The groups designated as Ec+Cy and EcCy+ served as positive controls
and were treated as follows: group Ec+Cy- was infected i.p. with 5 × 107
E. cuniculi spores, while group EcCy+ was treated only with CY. No treatment
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was done in Ec
Cy which served as negative control. Rabbits of groups Ec+Cy+
and Ec+Cy were kept individually and isolated from the other groups. The ani-
mals were killed in week 12 after the first application of CY. Body weight was
measured weekly.
Indirect immunofluorescence antibody test (IFAT)
The IFAT method was used to determine specific anti-E. cuniculi antibod-
ies. The method was performed according to Chalupský et al. (1973). Fresh sus-
pension of E. cuniculi from tissue culture was placed on each well of a slide. The
slides were air-dried for 24 h, then fixed in absolute acetone for 15 min and air-
dried. Rabbit sera tested were serially diluted beginning at 1:4 and ending at 1:512.
Each of the wells on the slide was covered with 10 µl diluted serum, and slides
were incubated for 30 min at 37 °C within a moist chamber. The slides were then
washed twice in distilled water and PBS at 10-min intervals. Following air-drying,
the wells were covered with 10 µl of swine anti-rabbit immunoglobulin fluorescein
isothiocyanate conjugate (SEVAC, Prague) of 1:160 dilution. After 30 min at
37 °C the slides were washed and air-dried. Then they were counter-stained with
Evans blue and coverslips mounted with buffered glycerine.
Blood leukocyte count
CY-induced immunosuppression was estimated by means of white blood
cell count. The blood samples were collected two weeks after primary CY treatment
and later biweekly from the marginal aural vein into Turks solution. The cells were
then counted in a haemocytometer. Differential cell counts were made on blood
smears after May-Grünwald-Giemsa staining by counting 100 leukocytes per slide.
Data evaluation
Results are quoted as the mean ± SEM. The data were statistically evalu-
ated by the one-way analysis of variance (ANOVA) with post hoc Bonferroni
multiple-comparison test. Differences between groups at the level of p < 0.05
were considered significant.
Results
Ec+Cy+ rabbits showed a significant decrease in body weight between
weeks 8 and 12 in comparison to the EcCy+ or Ec+Cy controls (Table 1). Three
Ec+Cy+ animals developed non-parasitic alopecia on the back, incontinent urina-
tion, ataxia, torticollis, convulsions, paresis and paralysis of the hind limbs in
week 5. These rabbits died in week 6. The above-mentioned alopecia was also
observed in the EcCY+ control.
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Table 1
Changes of body weight in E. cuniculi-infected rabbits during treatment with cyclophosphamide
Period after first Body weight (kg)
CY dosage (week) Ec+Cy+ Ec+Cy EcCy+ EcCy
2 2.69 ± 0.100 2.92 ± 0.122 2.73 ± 0.129 2.75 ± 0.085
4 2.46 ± 0.099 2.66 ± 0.114 2.59 ± 0.123 2.82 ± 0.065
6 2.50 ± 0.089 2.67 ± 0.084 2.56 ± 0.117 2.87 ± 0.085
8 2.48 ± 0.082
ab
2.68 ± 0.074 2.84 ± 0.097
a
2.92 ± 0.057
b
10 2.75 ± 0.094
a
2.69 ± 0.083
b
3.18 ± 0.121
ab
3.06 ± 0.059
b
12 2.72 ± 0.081
a
2.82 ± 0.078
b
3.06 ± 0.117
a
3.27 ± 0.066
ab
Same superscript means significantly different group *(p < 0.05) within the same week
Sera from both the Ec+Cy+ rabbits and Ec+Cy control reacted in the IFAT
by titres higher than 1:64 two weeks after the experimental E. cuniculi-infection.
Animals from other groups remained without specific anti-E. cuniculi antibodies
in the serum until the end of experiment.
Haematological analysis of Ec+Cy+ rabbits showed the following changes in
the number of white blood cells (WBC). Progressive decrease in WBC occurred in
weeks 4 and 6. In the same period, WBC count of Ec+Cy+ rabbits was significantly
lower in comparison to each control group (Table 2). Eosinophilia was noticed in
week 2 whereas severe eosinopenia was observed between weeks 4 and 6 (Table 3).
Basophils decreased in two phases, in weeks 6 and 12 (Table 4). The number of
peripheral lymphocytes sharply decreased up to week 6 (Fig. 1). Monocyte num-
bers declined in week 4 and then peaked in week 10 (Fig. 2). Heterophils de-
creased in two waves, the first in week 4, and the second in week 12 (Fig. 3). The
results of haematological examinations of the control groups are summarised in the
same tables and figures.
Table 2
White blood cell count in E. cuniculi-infected rabbits during treatment with cyclophosphamide
Period after first White blood cell count (10
9/l)
CY dosage (week) Ec+Cy+ Ec+Cy EcCy+ EcCy
2 8.10 ± 0.365 8.08 ± 0.413 7.90 ± 0.244a 9.46 ± 0.429a
4 6.38 ± 0.367
a
7.09 ± 0.611
b
7.17 ± 0.707
c
10.01 ± 0.419
abc
6 5.12 ± 0.390
a
7.12 ± 0.463
ab
7.76 ± 0.436
ac
9.76 ± 0.395
abc
8 5.33 ± 0.332
a
8.75 ± 0.325
ab
7.10 ± 0.259
abc
7.90 ± 0.376
ac
10 5.97 ± 0.397
a
8.35 ± 0.392
ab
5.32 ± 0.528
bc
10.00 ± 0.297
ac
12 5.58 ± 0.359
a
9.01 ± 0.338
ab
6.22 ± 0.424
bc
11.80 ± 0.391
ac
Same superscript means significantly different group *(p < 0.05) within the same week
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Table 3
Eosinophils in E. cuniculi-infected rabbits during treatment with cyclophosphamide
Period after first Eosinophils (10
9/l)
CY dosage (week) Ec+Cy+ Ec+Cy EcCy+ EcCy
2 0.041 ± 0.021 0.030 ± 0.037 0.021 ± 0.244 0.160 ± 0.037
4 0.010 ± 0.020 0.001 ± 0.018 0.001 ± 0.027 0.180 ± 0.029
6 0.001 ± 0.024 0.010 ± 0.027 0.013 ± 0.019 0.290 ± 0.037
8 0.020 ± 0.022 0.020 ± 0.040 0.023 ± 0.240 0.004 ± 0.146
10 0.010 ± 0.021 0.026 ± 0.028 0.011 ± 0.009 0.210 ± 0.042
12 0.110 ± 0.018 0.214 ± 0.035 0.022 ± 0.016 0.220 ± 0.040
Same superscript means significantly different group *(p < 0.05) within the same week
Table 4
Basophils in E. cuniculi-infected rabbits during treatment with cyclophosphamide
Period after first Basophils (10
9/l)
CY dosage (week) Ec+Cy+ Ec+Cy EcCy+ EcCy
2 0.110 ± 0.018 0.110 ± 0.010 0.051 ± 0.014 0.116 ± 0.034
4 0.012 ± 0.010
a
0.114 ± 0.001 0.043 ± 0.001 0.128 ± 0.038
a
6 0.071 ± 0.001
a
0.167 ± 0.001
b
0.066 ± 0.006
c
0.190 ± 0.039
abc
8 0.128 ± 0.007 0.144 ± 0.090 0.062 ± 0.010 0.049 ± 0.015
10 0.098 ± 0.009
a
0.139 ± 0.010 0.035 ± 0.006
a
0.102 ± 0.732
12 0.066 ± 0.006 0.234 ± 0.008 0.042 ± 0.007 0.155 ± 0.031
Same superscript means significantly different group *(p < 0.05) within the same week
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Fig. 1. Changes in the lymphocyte counts of E. cuniculi infected rabbits during cyclophosphamide
treatment. Same superscript means significantly different group *(p < 0.05) within the same week
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Fig. 2. Changes in the monocyte counts of E. cuniculi infected rabbits during cyclophosphamide
treatment. Same superscript means significantly different group *(p < 0.05) within the same week
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
2 4 6 8 10 12
Period after first cyclophosphamide dosage (week)
H
e
te
ro
p
h
il
c
o
u
n
ts
(1
0
9
/l
)
Ec+Cy+ Ec+Cy- Ec-Cy+ Ec-Cy-
Fig. 3. Changes in the heterophil counts of E. cuniculi infected rabbits during cyclophosphamide
treatment. Same superscript means significantly different group *(p < 0.05) within the same week
Discussion
Overt clinical signs of encephalitozoonosis in rabbits are variable, but in-
fection is usually subclinical. Rabbits occasionally develop motor paralysis, con-
vulsions and torticollis (Levkut et al., 1996). Currently, Pástorová et al. (1997)
have suggested that the level of catecholamine is significantly lower in spontane-
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ous cases of rabbit encephalitozoonosis. On the other hand, carnivores infected
with E. cuniculi were found to have retarded growth, total or partial blindness, bi-
lateral thickening of the irises, and dilatation of retinal vessels (Botha et al., 1979).
Moreover, ocular changes also include superficial and deep keratitis, retinitis and
cataracts (Arnensen and Norstoga, 1977). Carnivores are known to die of en-
cephalitis or uraemia due to chronic renal failure (Stewart et al., 1988).
We have found leukopenia and the decrease in white blood cell types. The
lowest count of peripheral leukocytes was observed from week 4 to week 6 of
the experiment in Ec+Cy+ rabbits. It is generally accepted that CY has a complex
immunomodulatory effect on diverse aspects of the immune response. It is me-
tabolised by hepatic microsomal cytochrome P-450 enzymes to several metabo-
lites such as 4-hydroxycyclophosphamide, phosphoramide mustard, acrolein,
and others. These diverse metabolites are responsible for mediating the thera-
peutic and toxic effects (Fox and McCune, 1994). Target tissues of CY include
the bone marrow as well as lymphoid cells and organs. In the spleen, a decrease
in T and B lymphocyte counts was recorded (Ladics and Loveless, 1994). Previ-
ous studies have led to the conclusion that lymphopenic leukopenia is the hall-
mark of CY immunomodulatory action in peripheral blood (Binta et al., 1996).
Significant body weight loss was found in Ec+Cy+ animals. Hair loss was
observed in Ec+Cy+ rabbits and EcCy+ controls from week 6. Neurological signs
were found in the Ec+Cy+ group while no control animals developed similar dis-
order. Loss of body weight, nonparasitic alopecia, neurological abnormalities,
anorexia and vomiting are known side effects of CY (Levkut, 1981).
At week 5, three Ec+Cy+ rabbits developed clinical signs of the disease such
as incontinent urination, ataxia, tremor, paresis and paralysis of hind limbs. Ani-
mals with clinical signs died in week 6 of CY treatment. It has been shown that en-
cephalitozoonosis remains latent as long as parasite multiplication and host im-
mune response are balanced. An intact thymus is required for protective immunity,
since euthymic BALB/c mice had chronic asymptomatic infections, while athymic
nude mice of this strain developed acute and lethal infections (Gannon, 1980). In
addition, previous studies demonstrated that pre-treatment of E. cuniculi with im-
mune sera reduced spore viability (Schmidt and Shadduck, 1984).
Our results showed that a low dose of CY given repeatedly can reactivate
latent encephalitozoonosis via immunosuppression. Rabbits under CY treatment
appear to be a useful model for the study of immunopathological mechanisms
involved in the interaction between E. cuniculi or other microsporidian patho-
gens and an immunodeficient host. Although the experiment demonstrated that
latent encephalitozoonosis developed into lethal disease as immunodeficiency
progressed, further studies are required to clarify whether a rabbit must be im-
munodeficient to become susceptible to manifest form of encephalitozoonosis.
92 HORVÁTH et al.
Acta Veterinaria Hungarica 47, 1999
Acknowledgement
We thank Mr. John A. Allen for excellent language correction of the manuscript.
This study was supported by the Scientific Grant Agency  grant no. 1/4223/97.
References
Arnensen, K. and Norstoga, K. (1977): Ocular encephalitozoonosis (nosematosis) in blue foxes:
polyarteritis nodosa and cataract. Acta Ophthalmol. 55, 641651.
Austin, H. A., Patel, A. D., Cadena, C. A., Boumpas, D. T. and Balow, J. E. (1997): Ongoing im-
munologic activity after short courses of pulse cyclophosphamide in the NZB/W murine
model of systemic lupus erythematosus. J. Rheumatol. 24, 6168.
Bálent, P., Kolodzieyski, L. and Hipíková, V. (1995): Encephalitozoonosis  an actual disease in
rabbits also in Slovakia (in Slovak). Slov. Vet. J. 20, 8183.
Binta, M. G., Mushi, E. Z. and Rurangirva, F. R. (1996): Effect of cyclophosphamide on the acqui-
sition of resistance to infestation by Rhipicephalus appendiculatus in rabbits. Onderste-
poort J. Vet. Res. 63, 710.
Botha, V. S., Van Dellen, A. F. and Stewart, C. G. (1979): Canine encephalitozoonosis in South
Africa. J. South Afr. Vet. Assoc. 50, 135144.
Boumpas, D. T., Chrousos, G. P., Wilder, R. L., Wilder, T. R., Cupps, T. R. and Balow, J. E.
(1993): Glucocorticoid therapy for immune-mediated diseases: basic and clinical corre-
lates. Ann. Inter. Med. 119, 11981208.
Bradley, J. D., Brandt, K. D. and Katz, B. P. (1989): Infectious complications of cyclophos-
phamide treatment for vasculitis. Arthritis Rheum. 32, 4553.
Chalupský, J., Vávra, J. and Bedrník, P. (1973): Detection of antibodies to Encephalitozoon cuniculi
in rabbits by the indirect immunofluorescent antibody test. Folia Parasit. 20, 281284.
De Forni, M. and Armand, J. P. (1994): Cardiotoxicity of chemotherapy. Curr. Opinion Oncol. 6,
340344.
Didier, E. S., Vossbrinck, C. R., Baker, M. D., Rogers, L. B., Bertucci, D. C. and Shadduck, J. A.
(1995): Identification and characterisation of three Encephalitozoon cuniculi strains. Para-
sitol. 111, 411421.
Fox, D. A. and McCune, W. J. (1994): Immunosuppressive drug therapy of systemic lupus erythe-
matosus. Rheum. Dis. Clin. North Am. 20, 265299.
Gannon, J. (1980): The course of infection of Encephalitozoon cuniculi in immunodeficient and
immunocompetent mice. Lab. Animals 14, 9194.
Koudela, B., Vítovec, J., Ditrich, O. and Trávnièek, J. (1993): The severe combined immunodefi-
cient mouse as a model for Encephalitozoon cuniculi microsporidiosis. Folia Parasit. 40,
279286.
Ladics, G. S. and Loveless, S. E. (1994): Cell surface marker analysis of splenic lymphocyte popula-
tions of the CD rat for use in immunotoxicological studies. Toxicol. Methods 4, 7791.
Levkut, M. (1981): Effect of cyclophosphamide on avian sarcoma infected rats. In: M. Levkut (ed.)
Pathomorphological Study of Avian Sarcomatosis (in Slovak). PhD Thesis, University of
Veterinary Medicine, Koice, pp. 105114.
Levkut, M., Leník, F., Bálent, P., Zajac, V., Korim, P. and Sláviková, K. (1997): Bovine leukemia
virus-induced clinical signs and morphological changes of encephalitozoonosis in rabbits.
Folia Parasit. 44, 249259.
LETHAL ENCEPHALITOZOONOSIS IN CYCLOPHOSPHAMIDE-TREATED RABBITS 93
Acta Veterinaria Hungarica 47, 1999
Levkut, M., Levkutová, M., Hipíková, V., Kolodzieyski, L., Bálent, P. and Bajová, V. (1996):
Demonstration of antibodies to Encephalitozoon cuniculi in rabbits on some Slovak farms.
Helminthologia 33, 2526.
Mathis, A., Michel, M., Muller, C., Weber, R. and Deplazes, P. (1997): Two Encephalitozoon cu-
niculi strains of human origin are infectious to rabbits. Parasitol. 114, 2935.
McCune, W. J., Golbus, J., Zeldes, W., Bohlke, P., Dunne, R. and Fox, D. A. (1988): Clinical and
immunologic effects of monthly administration of intravenous cyclophosphamide in severe
systemic lupus erythematosus. N. Engl. J. Med. 318, 14231431.
Pakes, S. P. and Gerrity, L. W. (1994): Protozoal diseases. In: Manning, P. J., Ringler, D. H. and
Newcomber, C. E. (eds) The Biology of the Laboratory Rabbit. Academic Press Inc., San
Diego, p. 215.
Pástorová, B., Rybo, M., Eliá, V. and Várady, J. (1997): Levels of catecholamines in blood plasma
of rabbits naturally infected with Encephalitozoon cuniculi. Helminthologia 34, 2326.
Schmidt, E. C. and Shadduck, J. A. (1984): Mechanisms of resistance to the intracellular protozoan
Encephalitozoon cuniculi in mice. J. Immunol. 133, 27122719.
Steinberg, A. D. (1993): Chlorambucil in the treatment of patients with immune mediated rheu-
matic diseases. Arthritis Rheum. 36, 325328.
Stewart, C. G., Reyers, F. and Snyman, H. (1988): The relationship in dogs between primary renal
disease and antibodies to Encephalitozoon cuniculi. J. South Afr. Vet. Assoc. 59, 1921.
Weber, R., Bryan, R. T., Schwartz, D. A. and Owen, R. L. (1994): Human microsporidial infec-
tions. Clin. Microbiol. Rev. 7, 426461.
